A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability

被引：38

作者：

Lacey, Judith ^{[1
,2
]}

Lomax, Anna J. ^{[1
]}

McNeil, Catriona ^{[1
,2
]}

Marthick, Michael ^{[1
]}

Levy, David ^{[1
,3
]}

Kao, Steven ^{[1
,2
]}

Nielsen, Theresa ^{[1
]}

Dhillon, Haryana M. ^{[3
]}

机构：

[1] Chris OBrien Lifehouse, Ctr Comprehens Canc, Missenden Rd, Camperdown, NSW, Australia

[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[3] Univ Sydney, Sch Psychol, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW, Australia

来源：

SUPPORTIVE CARE IN CANCER | 2019年 / 27卷 / 04期

关键词：

Metastatic melanoma; Immune checkpoint inhibitor; Immunotherapy; Oncology; Supportive care; Feasibility study; Pilot study; REPORTED OUTCOME MEASURES; FUNCTIONAL ASSESSMENT; CANCER; IPILIMUMAB; PEMBROLIZUMAB; POPULATION; MANAGEMENT; SURVIVAL; FATIGUE;

D O I：

10.1007/s00520-018-4524-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IntroductionIncreasing numbers of metastatic melanoma (MM) patients are receiving immunotherapy treatment, including pembrolizumab, and the impact on their well-being is underexplored.ObjectivesTo assess the feasibility of a multimodal supportive care program to MM patients being treated with pembrolizumab.MethodsThis pre-post-test feasibility cohort study recruited MM participants treated with pembrolizumab: (i) supportive care intervention with usual care and (ii) usual care. The intervention comprised comprehensive medical assessment by supportive care physician (SCP), exercise physiologist (EP), and dietitian then a tailored supportive care program. Programs included exercise, dietary advice, non-invasive complementary therapies, and psychology consultation. Outcome measures included adherence, patient-reported symptoms, anxiety and depression, and toxicity. Descriptive data are reported.ResultsWe recruited 28 participants: 13 intervention and 15 control; three did not complete the study. Most were male, with median age 66 (range 42-85) years. All intervention participants completed baseline assessments with SCP, EP, and dietitian. Two missed follow-up with EP or dietitian. Symptoms most troubling at baseline were as follows: fatigue (n=6), sleep (n=6), general aches and pains (n=5), and memory (n=4). All intervention participants were prescribed 16 exercise sessions; 8 (50%) completed all; overall exercise adherence was 85%. Integrative therapies were accessed by 85% (11) participants. Immunotherapy-related adverse event rates were low and SCP consultation identified symptoms not captured by CTCAE 4.0.ConclusionsA holistic supportive care intervention tailored to individual needs is feasible. The symptom burden in MM patients was low. Further investigation of the intervention is warranted, focused on populations with higher symptom burden to improve outcomes.

引用

页码：1497 / 1507

页数：11

共 39 条

[21] What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled Trials [J].

Kotronoulas, Grigorios ;

Kearney, Nora ;

Maguire, Roma ;

Harrow, Alison ;

Di Domenico, David ;

Croy, Suzanne ;

MacGillivray, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) :1480-+

[22]

Levy D, 2018, SUPPORT CARE CANC

[23] Living with advanced cancer and an uncertain disease trajectory: an emerging patient population in palliative care? [J].

Lobb, Elizabeth A. ;

Lacey, Judith ;

Kearsley, John ;

Liauw, Winston ;

White, Lesley ;

Hosie, Annmarie .

BMJ SUPPORTIVE & PALLIATIVE CARE, 2015, 5 (04) :352-357

[24] Integrative Oncology [J].

Lopez, Gabriel ;

Mao, Jun J. ;

Cohen, Lorenzo .

MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (05) :977-+

[25] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma [J].

Mahoney, Kathleen M. ;

Freeman, Gordon J. ;

McDermott, David F. .

CLINICAL THERAPEUTICS, 2015, 37 (04) :764-782

[26] Exercise interventions on health-related quality of life for people with cancer during active treatment [J].

Mishra, Shiraz I. ;

Scherer, Roberta W. ;

Snyder, Claire ;

Geigle, Paula M. ;

Berlanstein, Debra R. ;

Topaloglu, Ozlem .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (08)

[27] Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials [J].

O'Connor, Jeremy M. ;

Fessele, Kristen L. ;

Steiner, Jean ;

Seidl-Rathkopf, Kathi ;

Carson, Kenneth R. ;

Nussbaum, Nathan C. ;

Yin, Emily S. ;

Adelson, Kerin B. ;

Presley, Carolyn J. ;

Chiang, Anne C. ;

Ross, Joseph S. ;

Abernethy, Amy P. ;

Gross, Cary P. .

JAMA ONCOLOGY, 2018, 4 (08)

[28]

[Pharmaceutical Benefits Advisory Committee Health Do], 2018, SCHED PHARM BEN

[29] How to summarise and report written qualitative data from patients: a method for use in cancer support care [J].

Polley, Marie J. ;

Seers, Helen E. ;

Cooke, Helen J. ;

Hoffman, Caroline ;

Paterson, Charlotte .

SUPPORTIVE CARE IN CANCER, 2007, 15 (08) :963-971

[30] Nutritional assessment in cancer: Comparing the mini-nutritional assessment (MNA) with the scored patient-generated subjective global assessment (PGSGA) [J].

Read, JA ;

Crockett, N ;

Volker, DH ;

MacLennan, P ;

Choy, STB ;

Beale, P ;

Clarke, SJ .

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2005, 53 (01) :51-56

← 1 2 3 4 →